Ascelia Pharma ABCHIX:ACES 28 Market Cap is kr400.61 Mil as of Jun. 26, 2026. GuruFocus rates CHIX:ACES with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, Ascelia Pharma AB ranks worse than 65.83% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ascelia Pharma AB's share price for the quarter that ended in Mar. 2026 was kr45.05. Ascelia Pharma AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 126.87 Mil. Therefore, Ascelia Pharma AB's market cap for the quarter that ended in Mar. 2026 was kr5,715.45 Mil.
Ascelia Pharma AB's quarterly market cap
increased
from Sep. 2025 (kr5,713.02 Mil) to Dec. 2025 (kr5,715.45 Mil) but then
stayed the same
from Dec. 2025 (kr5,715.45 Mil) to Mar. 2026 (kr5,715.45 Mil).
Ascelia Pharma AB's annual market cap
increased
from Dec. 2023 (kr2,198.35 Mil) to Dec. 2024 (kr4,329.58 Mil) and
increased
from Dec. 2024 (kr4,329.58 Mil) to Dec. 2025 (kr5,715.45 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ascelia Pharma AB's Enterprise Value for Today is kr367.41 Mil.
Ascelia Pharma AB (CHIX:ACEs) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ascelia Pharma AB Market Cap Related Terms
Ascelia Pharma AB Market Cap Historical Data
* Premium members only.
The historical data trend for Ascelia Pharma AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ACES vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Ascelia Pharma AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascelia Pharma AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Ascelia Pharma AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ascelia Pharma AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascelia Pharma AB (CHIX:ACES) has a Market Cap of kr400.61 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #942 out of 1431 companies in the Biotechnology industry, placing it in the top 65.8%.
Is Ascelia Pharma AB's Market Cap too high?
Ascelia Pharma AB's current Market Cap is kr400.61 Mil. Based on the distribution chart, Ascelia Pharma AB ranks #942 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascelia Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #942 out of 1431 companies for Market Cap. This places Ascelia Pharma AB in the lower half of its industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ascelia Pharma AB and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascelia Pharma AB's current Market Cap is kr400.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (CHIX:ACES) has a current Market Cap of kr400.61 Mil. The current Market Cap is kr400.61 Mil. Ascelia Pharma AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ascelia Pharma AB (CHIX:ACES), the current Market Cap is kr400.61 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
28GF Score
Get the complete analysis for CHIX:ACES
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ACES has been successfully added to your 
